Host Defense Peptides Emerge as Promising New Strategy for Inflammatory Bowel Disease

Inflammatory bowel diseases (IBDs) are debilitating, chronic conditions characterized by severe inflammation and tissue damage in the gastrointestinal tract. Current therapeutic options often come with significant adverse side effects, highlighting an urgent need for safer and more effective alternatives. This review specifically addresses the therapeutic potential of host defense peptides (HDPs) as a novel drug lead for IBDs, leveraging their unique antimicrobial and immunomodulatory properties.

The review highlighted that HDPs exert their therapeutic effects primarily through immunomodulatory and antimicrobial properties, making them highly attractive candidates for IBD treatment. Specifically, many HDPs were found to downregulate the nuclear factor kappa B (NF-κB) pathway, a central regulator of inflammatory responses, thereby reducing inflammation. They also demonstrated the ability to modulate cytokine release, restoring a more balanced immune environment within the gut. The collective data strongly suggest that HDPs possess significant therapeutic potential for IBDs, offering a pathway to mitigate the severe inflammation and tissue damage with a reduced side effect profile compared to conventional therapies. This broad spectrum of activity across different peptide classes underscores their versatility in targeting various facets of IBD pathophysiology, from microbial dysbiosis to chronic inflammation.